Essentials of nuclear medicine imaging

Essentials of Nuclear Medicine Imaging

Volumn , Issue , 2012, Pages

  Mettler, Fred ^a   Guiberteau, Milton ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013848882     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2009-0-61619-6     Document Type: Book

References (138)

1. rd ed. In press). 2nd ed.
2. Hendee W.R., Ritenour E.R. Medical Imaging Physics 2002, Wiley-Liss, New York, chapters 2-4. 4th ed.
3. Silberstein E.B. Positron-emitting radiopharmaceuticals: how safe are they. Cancer Biother Radiopharm 2001, 16:13-15.
4. Silberstein E.B., Ryan J. Pharmacopeia Committee of the Society of Nuclear Medicine: Prevalence of adverse reactions in nuclear medicine. J Nucl Med 1996, 37:185-192.
5. Simpkin D.J. The AAPM/RSNA Physics Tutorial for Residents: Radiation interactions and internal dosimetry in nuclear medicine. RadioGraphics 1999, 19:155-167.
6. Buck A., Nekolla S., Ziegler S., et al. SPECT/CT. J Null Med 2008, 49:1305-1319.
7. Bushberg J.T., Seibert J.A., Leidholdt E.M., et al. The Essential Physics of Medical Imaging 2002, Williams & Wilkins, Baltimore. 2nd ed.
8. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med 2010, 37:662-671. European Association of Nuclear Medicine Physics Committee.
9. Madsen M.T. Recent advances in SPECT imaging. J Nucl Med 2007, 48:661-673.
10. Mawlawi O., Townsend D. Multimodality imaging: An update on PET/CT technology. Eur J Nucl Med 2009, 36(Suppl 1):S15-S29.
11. Patton J., Turkington T. SPECT/CT physical principles and attenuation correction. J Nucl Med Technol 2008, 36:1-10.
12. Pichler B.J., Kolb A., Nagele T., et al. PET/MRI: Paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010, 51:333-336.
13. Ranger N.T. The AAPM/RSNA Physics Tutorial for Residents: Radiation detectors in nuclear medicine. RadioGraphics 1999, 19:481-502.
14. Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: A brief review. J Nucl Med 2008, 49:1114-1131.
15. Bonte F.J., Devous M.D. SPECT brain imaging. Diagnostic Nuclear Medicine 2003, 757-782. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
16. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007, 48:1468-1481.
17. Conrad G.R., Sinha P. Scintigraphy as a confirmatory test of brain death. Semin Nucl Med 2003, 33:312-323.
18. Henry T.R., Van Heertum R.L. Positron emission tomography and single photon emission computed tomography in epilepsy care. Semin Nucl Med 2003, 33:88-104.
19. Kadir A., Nordberg A. Target specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med 2010, 51:1418-1430.
20. Lawrence S.K., Delbeke D., Partain C.L. Cerebrospinal fluid imaging. Diagnostic Nuclear Medicine 2003, 835-850. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
21. Matsuda H. Role of neuroimaging in Alzheimer's disease with emphasis on brain perfusion: SPECT. J Nucl Med 2007, 48:1289-1300.
22. Minoshima S., Frey K.A., Cross D.J., et al. Neurochemical imaging of dementias. Semin Nucl Med 2004, 34:70-82.
23. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med 2008, 35(Suppl 1):S46-S50.
24. Norfray J.F., Provenzale J.M. Alzheimer's disease: neuropathic findings and recent advances in imaging. AJR Am J Roentgenol 2004, 182:3-13.
25. Paschali A., Messinis L., Kargiotis O., et al. SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease. Eur J Nucl Med Mol Imaging 2010, 37:1128-1140.
26. Rastogi S., Lee C., Salamon N. Neuroimaging in pediatric epilepsy: a multimodality approach. RadioGraphics 2008, 28:1079-1095.
27. Waxman A., Herholz K., Lewis D., et al. Society of Nuclear Medicine Procedure Guideline for FDG PET brain imaging. Version 1.0 2009, Accessed June 28, 2011. http://www.snm.org/.
28. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-1214.
29. 99mTc-sestamibi SPECT and SPECT/CT. RadioGraphics 2008, 28:1461-1476.
30. Iagaru A., McDougall I.R. Treatment of thyrotoxicosis: continuing education. J Nucl Med 2007, 48:379-389.
31. Intenzo C.M., Capuzzi D.M., Jabbour S., et al. Scintigraphic features of autoimmune thyroiditis. RadioGraphics 2001, 21:957-964.
32. Intenzo C.M., dePapp A.E., Jabbour S., et al. Scintigraphic manifestations of thyrotoxicosis. RadioGraphics 2003, 23:857-869.
33. Release of patients after therapy with unsealed radionuclides. Annals of the ICRP 2004, 34(2). International Commission on Radiological Protection, Publication 94,.
34. Luster M., Clarke S.E., Dietlein M., et al. Guidelines for radiotherapy of differentiated thyroid cancer (European Association of Nuclear Medicine). Eur J Nucl Med Mol Imaging 2008, 35:1941-1959.
35. Mariani G., Gulec S.A., Rubello D., et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med 2003, 44:1443-1458.
36. Siegel J.A., Silberstein E.B. A closer look at the latest NRC patient release guidance. J Nucl Med 2008, 49(7):N17-N20.
37. Smith J.R., Oates M.E. Radionuclide imaging of the parathyroid glands: patterns, pearls, and pitfalls. RadioGraphics 2004, 24:1101-1115.
38. Procedure guideline for therapy of thyroid disease with iodine-131 (sodium-iodide) 9/17/2005, Society of Nuclear Medicine, Accessed June 26, 2011. http://www.snm.org/.
39. Procedure guideline for scintigraphy for differentiated papillary and follicular thyroid"cancer 9/5/2006, Society of Nuclear Medicine, Accessed June 26, 2011. http://www.snm.org/.
40. 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med 2010, 51(4):567-574.
41. Baggish A.L., Boucher C.A. Radiopharmaceutical agents for myocardial perfusion imaging. Circulation 2008, 118(16):1668-1674.
42. Bateman T.M., Heller G.V., McGhie A.I., et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006, 13:24-33.
43. Botvinick E.H. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol 2009, 37(1):14-25.
44. Einstein A.J., Moser K.W., Thompson R.C., et al. Radiation dose to patients from cardiac diagnostic imaging. Circulation 2007, 116(11):1290-1305.
45. Go V., Bhatt M.R., Hendel R.C. The diagnostic and prognostic value of ECG-Gated SPECT myocardial perfusion imaging. J Nucl Med 2004, 45:912-921.
46. Hachamovitch R., Berman D.S. The use of nuclear cardiology in clinical decision making. Semin Nucl Med 2005, 35:62-72.
47. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med 2005, 35(1):17-3536.
48. Meine T.J., Hanson M.W., Borges-Neto S. The additive value of combined assessment of myocardial perfusion and ventricular function studies. J Nucl Med 2004, 45:1721-1724.
49. Nichols K.J., Van Tosh A., Wang Y., Palestro C.J., Reichek N. Validation of gated blood-pool SPECT regional left ventricular function measurements. J Nucl Med 2009, 50(1):53-60.
50. Paul A.K., Nabi H.A. Gated myocardial perfusion SPECT: basic principles, technical aspects, and clinical applications. J Nucl Med Technol 2004, 32:179-187.
51. Salerno M., Beller G. Noninvasive assessment of myocardial perfusion. Circ Cardiovasc Imaging 2009, 2(5):412-424.
52. 82Rb. Health Phys 2010, 99(6):811-813.
53. Travin M.I., Bergmann S.R. Assessment of myocardial viability. Semin Nucl Med 2005, 35:2-16.
54. Anderson D.R., Kahn S.R., Rodger M.A., et al. Computed tomography pulmonary angiography vs. ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: A controlled randomized trial. JAMA 2007, 298(23):2743-2753.
55. Angelli G., Becattini C. Acute pulmonary embolism: Current concepts. N Engl J Med 2010, 363:266-274.
56. Line B.R. Scintigraphic studies of non-embolic lung disease. Diagnostic Nuclear Medicine 2003, 377-412. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
57. Reid J.H., Coche E.E., Inoue T., et al. Is the lung scan alive and well Facts and controversies in defining the role of lung scintigraphy for the diagnosis of pulmonary embolism in the era of MDCT. Eur J Nucl Med Mol Imaging 2009, 36:505-521.
58. Reinartz P. To PIOPED, or not to PIOPED. J Nucl Med 2008, 49(11):1739-1740.
59. SNM practice guideline for lung scintigraphy 4.0, 2011. http://interactive.snm.org/docs/Lung_scintigraphy_V4_Final pdf. Accessed September 16, 2011, Society of Nuclear Medicine.
60. Sostman H.D., Miniati M., Gottschalk A., et al. Sensitivity and specificity of perfusion scintigraphy combined with chest radiography for acute pulmonary embolism. J Nucl Med 2008, 49:1741-1748.
61. Sostman H.D., Stein P.D., Gottschalk A., et al. Acute pulmonary embolism: Sensitivity and specificity of ventilation-perfusion scintigraphy in PIOPED II study. Radiology 2008, 246(3):941-946.
62. Stein E.G., Haramati L.B., Chamarthy M., et al. Success of a safe and simple algorithm to reduce use of CT pulmonary angiography in the emergency department. AJR. Am J Roentgenol 2010, 194:392-397.
63. Stein P.D., Freeman L.M., Sostman H.D., et al. SPECT in acute pulmonary embolism. J Nucl Med 2009, 50:1999-2007.
64. Tunariu N., Gibbs S., Win Z., et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007, 48(5):680-684.
65. Donohoe K.J., Maurer A.H., Zeissman H.A., et al. Procedure guideline for adult solid meal gastric emptying study 3.0. . Accessed June 29, 2011 . http://www.snm.org/guidelines.
66. Mariani G., Pauwels E.K., AlSharif A., et al. Radionuclide evaluation of the lower gastrointestinal tract. J Nucl Med 2008, 49(5):776-787.
67. Society of Nuclear Medicine Procedure guideline for hepatobiliary scintigraphy, Version 4.0, approved 2010. . Accessed June 29, 2011. http://www.snm.org.
68. Urbain J.C., Vekemans M.M., Malmud L.S. Esophageal transit, gastroesophageal reflux and gastric emptying. Diagnostic Nuclear Medicine 2003, 487-502. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
69. Ziessman H.A. Acute cholecystitis, biliary obstruction and biliary leakage. Semin Nucl Med 2003, 33:279-296.
70. Zuckier L.S. Acute gastrointestinal bleeding. Semin Nucl Med 2003, 33:297-3311.
71. 18F bone scintigraphy: Basic principles, advanced imaging concepts, and case examples. J Nucl Med Technol 2007, 35(2):64-76.
72. Charron M., Brown M.L. Primary and metastatic bone disease. Diagnostic Nuclear Medicine 2003, 413-428. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
73. Chengazi V.U., O'Mara R.E. Benign bone disease. Diagnostic Nuclear Medicine 2003, 429-462. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
74. Dotan Z.A., Bianco F.J., Rabbani F., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005, 23(9):1962-1968.
75. 18F-fluoride PET/CT. J Nucl Med 2006, 47(2):287-297.
76. Fogelman I., Blake G.M. Different approaches to bone densitometry, continuing education. J Nucl Med 2000, 41:2015-2025.
77. Gomez P., Manoharan M., Kim S.S., et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: When is it indicated. BJU Int 2004, 94(3):299-302.
78. 18F-fluoride: Applying new technology to an old tracer. J Nucl Med 2007, 49(1):68-78.
79. Love C., Tomas M., Marwin S., et al. Role of nuclear medicine in diagnosis of the infected joint replacement. RadioGraphics 2001, 21:1229-1238.
80. 18F-fluoride PET/CT bone scans Version 1.0 approved 2010.Accessed September 21, 2011. http://www.snm.org.
81. Silberstein E.B., Buscombe J.R., McEwan A., et al. Society of Nuclear Medicine Procedure guidelines for palliative treatment of painful bone metastases Version 3.0 approved 2003.Accessed September 21, 2011. http://www.snm.org.
82. Barron B.J., Kim E.E., Lamki L.M. Renal nuclear medicine. Diagnostic Nuclear Medicine 2003, 865-902. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
83. Brown E.D., Chen M.Y.M., Wolfman N.T., et al. Complications of renal transplantation: Evaluation with US and radionuclide imaging. RadioGraphics 2000, 20:607-622.
84. Chong S., Lee K.S., Kim H.Y., et al. Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: Diagnostic efficacy and interpretation pitfalls. RadioGraphics 2006, 26:1811-1826.
85. Dubovsky E.V., Russel C.D. Evaluation of renal and pancreatic transplants. Diagnostic Nuclear Medicine 2003, 1037-1050. Lippincott Williams & Wilkins, New York. 4th ed. M.P. Sandler, R.E. Coleman, J.A. Patton (Eds.).
86. Elaini A.B., Shetty S.K., Chapman V.M., et al. Improved detection and characterization of adrenal disease with PET-CT. RadioGraphics 2007, 27:755-767.
87. Fine E.J. Diuretic renography and angiotensin converting enzyme inhibitor renography. Radiol Clin North Am 2001, 39:979-995.
88. Rossleigh M.A. Renal cortical scintigraphy and diuresis renography in infants and children. J Nucl Med 2001, 42:91-95.
89. Cole W.C., Barrickman J., Bloodworth G. Essential role of nuclear medicine technology in tositumomab and 131-tositumomab therapeutic regimen for non-Hodgkin's lymphoma. J Nucl Med Technol 2006, 34:67-73.
90. Intenzo C.M., Jabbour S., Lin H.C., et al. Scintigraphic imaging of body neuroendocrine tumors. RadioGraphics 2007, 27:1335-1369.
91. Hindie E., Groheux D., Brenot-Rossi I., et al. The sentinel node procedure in breast cancer: Nuclear medicine as the starting point. J, Nucl. Med 2011, 52:405-414.
92. Krynyckyi B.R., Kim C.K., Goyenechea M.R., et al. Clinical breast lymphoscintigraphy: Optimal techniques for performing studies, image atlas, and analysis of images. RadioGraphics 2004, 24:121-145.
93. Kwekkeboom D.J., Krenning E.P. Somatostatin receptor imaging. Semin Nucl Med 2002, 32:84-91.
94. Scarsbrook A.F., Ganeshan A., Statham J., et al. Anatomic and functional imaging of metastatic carcinoid tumors. RadioGraphics 2007, 27:455-476.
95. Schaffer N.G., Ma J., Huang P., et al. Radioimmunotherapy in non-Hodgkin lymphoma: Opinions of U.S. medical oncologists and hematologists. J Nucl Med 2010, 51:987-994.
96. 18F-FDG PET in neuroblastoma. J Nucl Med 2009, 50:1237-1243.
97. Society of Nuclear Medicine practice guideline for breast scintigraphy with breast specific gamma cameras Version 1.0, approved 2010, Accessed July 3, 2011. http://www.snm.org/.
98. Spies S.M. Imaging and dosing in radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004, 34:10-13.
99. Wahl R.L. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005, 46:S128-S140.
100. Uren R.F., Howman-Giles R., Thompson J.F. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med 2003, 44:570-582.
101. Zhu X. Radiation safety considerations radioimmunotherapy with yttrium-90 ibritumomab tiuxetan (Zevalin). Semin Nucl Med 2004, 34:20-23.
102. 67Ga SPECT in evaluation of lymphoma: comparative study. Radiology 2003, 227:353-360.
103. Basu S. PET and PET/CT in gastrointestinal stromal tumors: the unanswered questions and the potential newer applications. Eur J Nucl Med Mol Imaging 2010, 37:1255-1258.
104. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009, 50:88-99.
105. Buck A., Herrmann K., Stargardt T., et al. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med 2010, 51:401-412.
106. 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008, 49:179-185.
107. 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma. Eur J Nucl Med Mol Imaging 2010, 37:462-467.
108. 18F-FDG and SUV quantitation. Eur J Nucl Med Mol Imaging 2010, 37:1087-1094.
109. Hustinx R., Lucignani G. PET/CT in head and neck cancer: an update. Eur J Nucl Med Mol Imaging 2010, 37:645-651.
110. 18F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010, 37:284-300.
111. Kazama T., Faria S.F., Varavithya V., et al. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. RadioGraphics 2005, 25:91-207.
112. Kim T.J., Kim H.Y., Lee K.W., et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. RadioGraphics 2009, 29:403-421.
113. 18F-FDG PET/CT in colorectal liver metastases: comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008, 35:1323-1329.
114. Lim H.S., Yoon W., Chung T.W., et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. RadioGraphics 2007, 27:S197-S213.
115. Lim S.L., Yun M.J., Kim M.J., et al. CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. RadioGraphics 2006, 26:143-156.
116. Lucignani G. FDG-PET in gynecological cancers: recent observations. Eur J Nucl Med Mol Imaging 2008, 35:2133-2139.
117. Prakash P., Cronin C., Blake M. Role of PET/CT in ovarian cancer: Review. Am J Roentgenol 2010, 194(6):W464-W470.
118. Rosen E.L., Eubank W.B., Mankoff D., et al. FDG PET, PET/CT, and breast cancer imaging. RadioGraphics 2007, 27:S215-S299.
119. Veit-Haibach P., Vogt F.M., Jablonka R., et al. Diagnostic accuracy of contrast enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging 2009, 36:910-918.
120. Zaheer A., Cho S., Pomper M. New agents and techniques for imaging prostate cancer. J Nucl Med 2009, 50:1387-1390.
121. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Molec Imaging 2008, 35:1537-1543.
122. Gotthardt M., Bleeker-Rovers C., Boerman O., et al. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med 2010, 51:1937-1949.
123. Kwee T., Kwee R., Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur J Nucl Med Molec Imaging 2008, 35:2122-2132.
124. Love C., Marwin S.E., Palestro C.J. Nuclear medicine and the infected joint replacement. Semin Nucl Med 2009, 39(1):66-78.
125. Love C., Palestro C.J. Radionuclide imaging of infection: continuing education. J Nucl Med Tech 2004, 32:47-57.
126. Love C., Tomas M.B., Tronco G.G., et al. FDG PET of infection and inflammation. RadioGraphics 2005, 25:1357-1368.
127. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007, 48(1):35-45.
128. Palestro C.J. Radionuclide imaging of infection: in search of the grail. J Nucl Med 2009, 50(5):671-673.
129. 111In-oxine labeled leukocytes for detection of infection. Radiology 2006, 238:978-987.
130. Sathekge M., Goethals I., Maes A., et al. Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Molec Imaging 2009, 36:1176-1184.
131. Ionizing radiation exposure of the population of the United States. Report 160 2009, National Council on Radiation Protection and Measurements, Bethesda, Md.
132. RADAR Medical Procedure Radiation Dose Calculator and Consent Language Generator Radiation Dose Assessment Resource, Accessed February 22, 2011. http://www.doseinfo-radar.com/RADARDoseRiskCalc.html.
133. Radiation protection for medical and allied health personnel. Report no. 105 1989, National Council on Radiation Protection and Measurements, Bethesda, Md.
134. Procedure guideline for the use of radiopharmaceuticals 4.0 Society of Nuclear Medicine, Accessed on July 4, 2011. http://www.snm.org/guidelines.
135. Sources and magnitude of occupational and public exposures from nuclear medicine procedures. Report no. 124 1996, National Council on Radiation Protection and Measurements, Bethesda, Md.
136. United States Nuclear Regulatory Commission. Consolidated guidance about materials licenses. Program-Specific Guidance About Medical Use Licenses NUREG-1556, Vol 9, Rev 1, May 2005, Washington, DC. (This has model procedures and is available at .) . http://www.nrc.gov/.
137. NRC Regulations, Title 10, Code of Federal Regulations United States Nuclear Regulatory Commission, Accessed February 22, 2011. http://www.nrc.gov/reading-rm/doc-collections/cfr/.
138. Saremi F., Jadvar H., Siegel M.E. Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results. Radio Graphics 2002, 22:477.